

IMMUNE PROFILING



WORLD CONGRESS

2ND ANNUAL

OCTOBER 10-12, 2017
BARCELONA

Science, new
technology and strategy
for the veterinary
vaccine sector.

CO-LOCATED WITH

CREATED BY

WORLD VACCINE
EUROPE

WORLD VETERINARY
VACCINE CONGRESS

SPARK SOMETHING
TERRAPINN

#WVCEU • terrapiinn.com/ImmuneEU17

Contents


Overview	5
Scientific Advisory Board	6
Agenda overview	7
Day 1 combined	8-9
Day 2 & 3 of the 18th World Vaccine Congress	10-13
Day 2 & 3 of the 2nd Immune Profiling World Congress	14-17
Day 2 & 3 of the 3rd World Veterinary Vaccines Congress	18-21
Interactive Roundtables	22
Who attends and Why?	23-24
Floor plan	25-26
2017 Sponsors and Exhibitors	27
Book to Attend	28-30

NEW VACCINE & IMMUNE PROFILING TECHNOLOGY IS CHANGING THE WHOLE INDUSTRY

Make sure you are at the forefront of the vaccines industry. No matter where your interest lies, at the 18th annual **World Vaccine Congress, World Veterinary Vaccine Congress** and **Immune Profiling World Congress**, we have content, networking and potential partners for you.

By bringing experts from the whole value chain under one roof, you get to choose the sessions which are the most applicable to help your business plan for the future of vaccine research, development and manufacture.

Take just three days out of the office to meet with **450+ potential customers** who need to find solutions to challenges around the commercial and scientific issues in **manufacturing, trials, strategy, regulation, veterinary, immune profiling, respiratory, therapeutic and emerging diseases** vaccines.



OUR SCIENTIFIC ADVISORY BOARD



Prof Albert Osterhaus

Director Research
Center for Emerging
Infections and
Zoonoses (RIZ)
**University of
Veterinary Medicine
Hannover**



Dr Jeffrey Almond

Former Vice President
Discovery Research
and Development,
Sanofi and Visiting
Professor
University of Oxford



Dr Jan Poolman

Head Bacterial Vaccine
Discovery and Early
Development
**Janssen Infectious
Diseases and Vaccines**



Dr Jerald Sadoff

Senior Advisor Vaccine
Development
**Janssen Infectious
Diseases and Vaccines**



Dr Antu Dey

Senior Director,
Research &
Development
**International AIDS
Vaccine Initiative (IAVI)**



Dr Konrad Stradler

Head of R&D Vaccines
Boehringer Ingelheim



Dr Roy Baynes

Senior Vice President
Global Clinical
Development and
Chief Medical Officer
MSD



Dr Nathalie

Garçon
CEO & CSO
BIOASTER



Dr Cyril Gay

Senior National
Program Leader, Office
of National Programs
USDA



Dr Rino Rappuoli

Chief Scientist
GSK Vaccines



Dr Mahesh Kumar

Vice President, Global
Biologics Research
Zoetis



Dr Bernard Vallat

Honorary Director
General
**Office International
Des Epizooties**

2017 AGENDA OVERVIEW

DAY 1	DAY 2	DAY 3
Human Keynote Plenary	Human Keynote Plenary	Streams And Co-Conferences
	 Veterinary Congress	Immune Profiling Congress
Break	Break	New Vaccine Technology Bacterial Vaccines & Anti-Microbial Resistance Technology Supporting Delivery & Manufacture
Streams And Co-Conferences	Roundtables	Veterinary Vaccine Congress Immune Profiling Congress
Therapeutic & Immunotherapy Vaccines Influenza and Respiratory One Health	 Streams And Co-Conferences Emerging & re-emerging Clinical Development in Viral Early Development Veterinary Congress	Human Keynote Plenary 

DAY 1 AGENDA

PLENARY SESSION

08:30	Chair's opening remarks		
08:40	OPENING PLENARY DISCUSSION: Creating a new strategy: How does the current global outbreak response system need to change? - Efforts to develop an international fund to develop vaccines that are of low commercial interest but potentially epidemic-proof to the next emerging disease - Understanding the legal and regulatory framework for licensure of medical countermeasures during public health emergencies - How do we know which vaccines to stockpile? Initial efforts in MERS-CoV, Lassa and Nipah viruses - How should pharma and industry respond to developing low income vaccines? - What's the global capacity and how fast can we develop a sustainable supply?  Richard Hatchett CEO CEPI  Dr Marie-Paule Kieny Assistant Director-General - Health Systems and Innovation WHO  Dr K. Vijay Raghavan Secretary, Department of Biotechnology Ministry of Science and Technology, India		
09:40	Maternal immunisation: Where do we stand and how do we use vaccines, antivirals and antibodies - What's the strategy? - Are we vaccinating mums to protect the young or vaccinating the young to protect the elderly? - How will we integrate vaccines and other therapeutics to manage maternal immunisation?  Dr Jacqueline Miller VP Clinical R&D, GSK Vaccines US R&D Center GSK Vaccines		
10:10	NEW: Speed networking - Break the ice with your peers! <i>Allowing conference delegates to meet each other for a short space of time and exchange business cards. A unique feature guaranteeing heightened networking for all participants</i>		
10:40	Morning Networking Break		
	RESPIRATORY VACCINES TRACK  Pages 8 - 10	THERAPEUTIC VACCINES TRACK WITH  Pages 8 - 10	ONE HEALTH WORKSHOP WITH  Pages 8 - 10
11:40	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks Nathalie Garcon , CEO/CSO, BIOASTER
	INFLUENZA VACCINES	THERAPEUTIC & IMMUNOTHERAPY VACCINES	DISCOVERY AND DRIVERS FOR EMERGING DISEASES
11:45	As more universal flu candidates come to light, what are the clinical development plans? Dr Ted Ross , Director of Center for Vaccines and Immunology, University of Georgia	Using DNA vaccine based technology to prevent potentially life threatening allergies Dr Salim Mujais , SVP, Therapeutic Area Head Immunology, Transplant, Infectious Disease, CNS and Pain, Astellas Pharma	Bringing together experts in human and animal health to create new platforms and technologies that will facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge Dr Jean-Christophe Audonnet , Senior Director, Research Strategy, Key Alliances, Bio R&D, Meriel and Coordinator, ZAPI Dr Bart Haagmans , Working Group Leader, Department of Viroscience, Erasmus M.C., Co-coordinator, ZAPI
12:15	Clinical development of a nasal inactivated influenza vaccine Dr Anna-Karin Maltais , CSO, Eurocine Vaccines	Why haven't Alzheimer's vaccines succeeded yet? Prof Nikolai Petrovsky , Professor, Flinders University School of Medicine, Director, Vaxine Pty	

12:45	Assays used for vaccine efficacy studies and correlates of protection for influenza vaccines evaluation Prof Emanuele Montomoli , Professor at the Public Health University of Siena & CSO, VisMederi	How can lessons learned from current immunotherapy approaches in development for HIV help us tackle other chronic diseases? Dr Maja Sommerfelt Grønvold , Chief Scientific Officer, Bionor Pharma	Virus discovery - new kids on the block with pandemic potential Prof Albert Osterhaus , Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover
13:00	Oral tablet vaccines for the prevention of norovirus or influenza Dr Sean Tucker , CSO, Vaxart		
13:15	Networking Lunch & Poster Session		
14:45	Progress and potential hurdles for development of a universal flu vaccine Dr Jerald Sadoff , Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines	CANCER VACCINES T-cell response and recognition: Understanding the complex relationship to tumour resistance	The Global Virome Project: Bringing an end to pandemics Dr Peter Daszak , President, EcoHealth Alliance
15:15	The challenge of childhood influenza vaccination in Europe Dr Ruprecht Schmidt-Ott , European Director for Scientific Affairs & Public Health, GSK Vaccines	Personalized cancer vaccines that target patients-specific mutations Dr Karin Jooss , Chief Scientific Officer, Gritstone Oncology, Inc.	Use of vaccination in animals for total epizootic disease eradication and anti-microbial resistance control Dr Joseph Domenech , Consultant, ex World Animal Health Organization (OIE) Chargé de Mission and FAO Head of Animal Health Service
15:45	Immunogenicity of a plant-derived quadrivalent VLP vaccine in adults and the elderly Senior representative, Medicago	Data supporting the value of check point inhibitors, AMPLIVANT SLP conjugates and neoantigens in combinational immunotherapy against HPV cancers Willem-Jan Krebber , COO, ISA pharmaceuticals	The role of novel diagnostic methods in protecting both animals and humans
16:15	Networking Break		
16:45	Update on the Ph I intranasal RSV vaccine SynGEM Dr Kees Leenhouts , CSO, Mucosis	The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics Dr Angus Dalglish , Foundation Chair, Clinical Oncology, Research Director, St George's University, London	New insight and the challenges associated with the prevention and control of Rift Valley fever Dr Osama Ahmed Hassan Ahmed , epidemiologist, Public Health Institute & Umea University
17:00	Landscape analysis of RSV vaccine development and future implications Dr Marta Nunes , Respiratory and Meningeal Pathogens Research Unit, University of Witwatersrand, Soweto South Africa		
17:15	Update on the development of the recombinant RSV vaccine candidate MVA-BN® RSV Dr Nathaly Samy , Senior Vice President Clinical Development, Bavarian Nordic	Oncolytic viruses as immunotherapy - Establishing the legitimacy of oncolytic viruses in cancer therapy Dr Brian R. Champion , CSO, PsiOxus Therapeutics	Development of proprietary polysaccharide vaccine adjuvants that meet the needs of humans and animals when concerning Influenza, West Nile and other re-emerged viruses Dr Nikolai Petrovsky , Chairman, Vaxine Pty
17:30	Developments and updates on the RSV F RSV Vaccine to protect infants via maternal immunization		
17:45	Chair closing remarks of day one followed by Drinks Reception		

DAY 2 AGENDA

PLENARY SESSION

09:00	Chair's opening remarks		
09:10	PLENARY DISCUSSION: Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia - The role of emerging markets in the global supply and demand for vaccines - What vaccine technologies and vaccine candidates are favourable? - Does it align with other philanthropy organisations? - The role of Public-Private Partnerships (P2Ps) in vaccine R&D for poverty related and neglected diseases (PRNDs) - Priorities for linking new vaccine development with public health in low and middle income countries  Dr Suresh Jadhav Executive Director Serum Institute of India  Dr K. Vijay Raghavan Secretary, Department of Biotechnology Ministry of Science and Technology, India  Dr David Shao CFO YISHENG Biopharma  Dr Krishna Ella Founder and Chairman Bharat Biotech  Dr Jean Lang Associate Vice President R&D Policy Head, Sanofi Pasteur  Dr Michael Makanga Executive Director European & Developing Countries Clinical Trials Partnership (EDCTP)  Yves Leurquin Head, Vaccines Market Access TakePharmaceuticals International		
10:10	Where are we in polio eradication? What are the remaining challenges? - How we will maintain a polio-free world - Are new/different vaccines required in the post eradication era?  Dr Phil Minor, Deputy Director, Head of Virology, NIBSC & Member of the WHO Advisory Panel on Biological Standardization		
10:40	Morning Networking Break		
11:40	Interactive Roundtables Choose 2 x 45 min long roundtables for these interactive discussions with like-minded peers tackling the same challenges - for more information go to page 17		
13:10	Networking Lunch & Poster Session		
	EMERGING & RE-EMERGING DISEASES	CLINICAL DEVELOPMENT IN VIRAL VACCINES	EARLY DEVELOPMENT & MANUFACTURING
14:40	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks
	BIOPREPAREDNESS AND VACCINE PROGRESSION	CLINICAL OUTCOMES IN VIRAL VACCINES	NEW PLATFORMS AND PROCESS DEVELOPMENT
14:45	How close are we to developing a Zika vaccine and when will more susceptible areas benefit from it?	The challenges of clinical development for emerging infectious diseases - The Example of Ebola Dr Melanie Saville , VP, Head of Late Development, Clinical and Medical Affairs, Janssen	Pre- formulation and stability studies in different vaccines - Key considerations Dr Florence Arvis , Head of Formulation Unit, Sanofi

15:15	Insights from serum antibody response profiling during a malaria vaccine field trial and after zika virus infection Dr John Tan, Senior Scientist, Technology Innovation, Roche Sequencing Solutions	Vaccines and Viral Challenge Agents - What's the difference? Senior representative, SGS Life Sciences	Development of a breakthrough vaccine manufacturing platform to radically lower costs increasing affordability and availability in developing countries Senior representative, Batavia Biosciences
15:30			Purification of vaccines by affinity chromatography based on 2 innovative nanotechnologies Senior representative, DiViNe Project
15:45	Networking Break		
16:15	Developing a universal vaccine against emerging mosquito-transmitted diseases and influenza Gregory Stoloff, CEO, SEEK	Ph2a studies for a preventive vaccine against the clade B HIV Dr Farshad Guirakhoo, CSO, Geovax	The rise of RNA vaccines: Practical considerations in bioprocessing and production
16:30			MACIVIVA - Developing cold chain independent virosomal vaccines Dr Sylvain Fleury, CSO, Mymetics
16:45	From vaccines research to launch of Dengvaxia and collaborative efforts to create a Zika vaccine Dr Jean Lang, Associate Vice President, R&D Projects Global Health, Partnerships & Funding, Sanofi Pasteur	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges	Challenges of RSV vaccine development Rob Dekker, CMC Team Lead, Janssen Infectious Diseases and Vaccines
17:00			INTERACTIVE PANEL: Accelerated development of vaccine products to human clinical trials - Successes and challenges Dr Antu Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative (IAVI) Dr Kunal Aggarwal, Head of Technical R&D Programs - R&D Center USA, GSK Vaccines Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines
17:15	Preventing the pandemic potential of MERS-CoV: Updates on research and clinical development Dr James Cummings, Senior Director of Clinical Development, Novavax	Standardization and development of assays for assessment of influenza vaccines correlates of protection Patricia Londono-Hayes, Head R&D Initiatives Europe, Sanofi	
17:45	Chair's closing remarks followed by MEET & GREET WITH KEY SPEAKERS in the EXHIBITION HALL		

DAY 3 AGENDA

	NEW TECHNOLOGY & DISCOVERY	BACTERIAL VACCINES & ANTI-MICROBIAL RESISTANCE	TECHNOLOGY SUPPORTING DELIVERY & MANUFACTURE
09:00	Chair's opening remarks Dr Jeffrey Almond , Former Vice President Discovery Research and Development, Sanofi and Visiting Professor, University of Oxford	Chair's opening remarks Dr Jan T Poolman , Head Bacterial Vaccine Discovery and Early Development, Janssen	Chair's opening remarks Dr Antu Dey , Senior Director, Research & Development, International AIDS Vaccine Initiative (IAVI)
		TUBERCULOSIS SYMPOSIUM	
09:10	TECHNOLOGY SHOWCASE 1 Proprietary VLP technology for developing safe and efficacious vaccines against enteroviruses and FMD Dr Jane Cardosa , CSO, Sentinx Therapeutics	The role of vaccines to combat antibiotic-resistant bacteria - WHO perspective Dr Martin Friede , Group Lead, Transfer of Technology for Health Products, WHO	Manufacturing capacity planning for Live Virus Vaccines and its impact on product development priorities Dr Trent Carrier , Vice President - Vaccine Technology and Engineering, Takeda
	TECHNOLOGY SHOWCASE 2 Use of MAV-VLP platform for development of vaccines for infectious diseases and cancer Dr Farshad Guirakhoo , CSO, Geovax		
09:40	TECHNOLOGY SHOWCASE 3 Using mAbs for targeted immunotherapy against bacterial infections Dr Eszter Nagy , Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH	TB vaccine candidates in early development	Virus safety for viral vaccines and viral vectors Dr Anissa Boumlic-Courtade , Vaccine Market Lead, EMEA, Merck
	TECHNOLOGY SHOWCASE 4 Structure-based design to tackle vaccine challenges Hans (JPM) Langedijk , Director Subunit Vaccine Design, Janssen Infectious Diseases and Vaccines		
10:10	TECHNOLOGY SHOWCASE 5 The next generation of conjugate vaccine against <i>Streptococcus pneumoniae</i> infection: A novel bioconjugation approach Dr Amir Faridmoayer , Co-Founder & Vice President Discovery, LimmaTech Biologics	Prevention of relapse after Abx treatment Dr Steve Reed , Founder, President and Chief Scientific Officer, IDRI	Viral vectors as vaccine platforms: From immunogenicity to impact Dr Katie Ewer , Senior Immunologist, Supervisor, Jenner Institute, Oxford University
10:25	TECHNOLOGY SHOWCASE 6 Flu pandemic response technologies		Advances in intradermal drug delivery Dr Yotam Levin , CEO, NanoPass Technologies Glen Zimmermann , Sr. Director, Business Development, Administration Systems, West Pharmaceutical Services
10:40	Networking Break		
11:20	TECHNOLOGY SHOWCASE 7 Comparing progress in RNA vaccines	BACTERIAL VACCINES IN CLINICAL DEVELOPMENT Extraintestinal pathogenic <i>E. coli</i> : Challenges for vaccine development and clinical progress Dr Jan T Poolman , Head Bacterial Vaccine Discovery and Early Development, Janssen	What's the future of vaccine manufacturing? Value-driven designs that companies can realistically adapt to and a review of current manufacturing processes

11:40	TECHNOLOGY SHOWCASE 8	Clinical update on the <i>Staphylococcus aureus</i> multi-antigen vaccine Dr Annaliesa Anderson , Vice President and CSO Bacterial Vaccines, Pfizer	Overview of the challenges and opportunities presented by plant-based vaccine manufacturing Dr Vidadi Yusibov , Executive Director, Fraunhofer USA
12:00	TECHNOLOGY SHOWCASE 9	The threat GAS as AMR rises and the promise of a vaccine Prof David Goldblatt , Professor of Vaccinology and Immunology, UCL	Industry perspective on handling the complex and sometimes undefined regulatory requirements
12:20	Networking Lunch		

PLENARY SESSION

13:20	Chair's opening remarks		
13:30	Vaccines against antibiotic resistance: The PCV paradigm - Using PCVs to reduce antibiotic resistance by reducing the vaccine serotype distribution - The significance of reducing antibiotic use in children and consequently rest of the population - What needs to be done with the appropriate education of reduced antibiotic abuse  Prof Ron Dagan , Professor of Paediatrics and Infectious Diseases, Paediatric Infectious Disease Unit, Soroka University Medical Center		
14:05	How does our microbiome affect the way we respond to vaccines and its effectiveness in preventing disease? - Understand the Microbiome and its interaction with the immune system - How to effectively manipulate the microbiome to improve vaccine efficacy - Potential opportunities and current challenges  Dr Vanessa Harris , Amsterdam Institute for Global Health and Development, University of Amsterdam		
14:55	PLENARY DISCUSSION: Vaccines don't protect, vaccination does - How much damage is done with the wrong information? - The use of vaccines or the failure to do so - Why make new vaccines if we have old ones that work but aren't being used? - Paving the way for a framework capable of rapidly delivering reliable data on the benefits and risks of vaccines that are on the market  Prof Albert Osterhaus , Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover  Dr Norman Begg , Chief Medical Officer, GSK Biologicals <i>More panellists to be confirmed</i>		
15:40	Chair's closing remarks and close of Congress		

DAY 2 AGENDA

08:30 Chair's opening remarks

EXCITING IMMUNE-MANIPULATION APPROACHES

08:40 Development of TCR based adoptive T-cell therapies: Opportunities and challenges

- Discovery and development of T-cells for immunotherapies
- Identifying patient populations and expanding the responding population
- TCR targeting of neoantigens
- Addressing potential challenges in cell based immunotherapies



Dr Kai Pinkernell,

Chief Medical Officer and Senior Vice President of Medical Affairs,
Medigene

09:10 Combinational immunotherapy in oncology: Increasing the effective targeting of neo-epitopes

- PD-1 Antibodies have the potential to be a broad spectrum antineoplastic treatment both as monotherapy and in combination therapies
- Discussing the efficacy and toxicity profiles of therapeutic combinations
- Current opportunities, challenges and the potential for unforeseen side effects
- Thoughts for the future for combination immunotherapy in oncology



Dr Emmett V. Schmidt MD PhD,

Executive Director, Clinical Research,
Merck Research Laboratories - Oncology

09:40 The role of the microbiota in cancer immune response during immunotherapeutic treatment

- Sharing recent advances in our understanding of host immunity in relation to the gut microbiota
- Exploring how the gut microbiota controls immune responses during cancer therapy
- How to exploit this knowledge within the clinical setting and challenges in doing so

10:10 Leveraging the potential of the innovative LADD program to develop personalized immunotherapies

- Personalized medicine treatment approach by targeting patient-specific neo-antigens
- Discussing strategy and sharing preclinical and PhI data supporting the clinical development programme for pLADD immunotherapy
- Is a personalised medicine approach the next trend in immunotherapy?



Tom Dubensky,

Chief Scientific Officer,
Aduro BioTech Inc

10:40 Morning Networking Break

11:40 Advanced development of innovative immunotherapeutics: In combination and exploiting the DART platform

- Overview of current progress, lessons learned, and future prospects for the combination immunotherapy of cancer
- Discussing how application of the DART platform leads to enhanced checkpoint blockade
- Mechanisms by which anti-tumour immune responses can be evoked when employing the novel DART platform



Dr Paul Moore,

Vice President-Immunology & Cell Biology,
MacroGenics

IMMUNE RESPONSE AND BIOMARKERS: B-CELL & T-CELL ANALYSIS

12:10 High-resolution profiling of antibody responses to arrays of peptides

- Applications in vaccines, oncology, autoimmune disorders, antibody discovery



Bradley Garcia,

Strategic Technology Commercialization Leader,
Roche Sequencing Solutions

12:25	High-throughput sequencing for the T-cell and B-Cell repertoire profiling - Effectively employing high-throughput sequencing for advanced profiling - Exploiting computational tools for the profiling of T-cell and B-cells for therapeutic developments
12:40	Harnessing T cells to develop an innovative immunotherapy that provide patients with access to a promising new treatment for cancer - Designing and employing MHRA approved adaptive clinical trials. Challenges faced and steps taken to overcome hurdles - Next steps and considerations for commercialisation
13:10	Networking Lunch & Poster Session
14:40	Improving the anti-tumour immune response through the use of bi-and trifunctional antibody-cytokine fusion proteins - Designing bi- and trifunctional antibody-fusion proteins with IL-15 and costimulatory members of the B7 and TNF superfamily - Sharing research which shows enhanced immune responsiveness in vitro and anti-tumour activity in a mouse model in vivo - Discussing mode of action employed  Dr Dafne Mueller, Group Leader, Institute of Cell Biology and Immunology, University of Stuttgart
15:10	Accuracy and prediction in antibody repertoire analysis - Novel error and bias correction of antibody repertoire data - Combining repertoire analysis with machine learning methods for predicting antigen exposure and specificity - Functional screening of antibody repertoires using mammalian surface display technology  Dr Sai Reddy, Assistant Professor of Bimolecular Engineering, E.T.H. Zurich
15:45	Networking Break
16:15	Adjuvant profiling and systems analysis of vaccine induced response to enhance correlates of protection of human vaccines - Learn opportunities offered by systems analysis of response to human vaccines and adjuvants to inform rational vaccine development - Discussing the significance of new biomarkers in vaccine development - Sharing ongoing efforts within EU financed research programmes  Dr Ali Harandi, Associate Professor, Lab head, University of Gothenburg
16:45	Patient stratification for immunotherapy: tailoring drug design to molecularly defined cancer patient populations - Developing the first and only anti-PDL1 cancer immunotherapy Tecentriq® (Atezolizumab) approved by the FDA for people with the specific metastatic non-small cell lung cancer - The Atezolizumab combination approach to maximise efficacy - Challenges faced and lessons learnt  Dr Jun Wang, MD PhD, Senior Medical Director, Cancer Immunotherapy, Genentech/Roche, Product Development Oncology, Cancer Immunotherapy Franchise
17:15	Chair's closing remarks followed by MEET & GREET WITH KEY SPEAKERS in the EXHIBITION HALL

DAY 3 AGENDA

09:00 Chair's opening remarks

IMMUNE RESPONSE AND BIOMARKERS: B-CELL & T-CELL ANALYSIS

- 09:10 Application of sequential vaccination for educated immune responses
- Employing single cell transcriptomics and advanced X-50 flow cytometry technologies to illicit an educated immune response within HIV patients
 - Sharing exclusive clinical data
 - Highlighting the wider potential for single cell transcriptomics and X-50 technology within the vaccination field



Adrian McDermott,
Acting Chief,
Immunology Core, Vaccine Research Center, NIAID

- 09:40 Accelerating innovation with single-cell RNA genome sequencing
- Generating many new insights into complex biological systems, ranging from the diversity of microbial ecosystems to the genomics of human cancer
 - Current state of the field: technical challenges and the discovery of unexpected new biology
 - Predicting advances in the next few years

- 10:10 Developing effective biomarker strategies for advanced clinical development of Immune mobilising monoclonal TCRs against cancer (ImmTACs)

- Sharing updates on the phase I/IIa clinical trials in advanced melanoma
- Employing a unique biomarker strategy which allows for comprehensive analysis of markers within the tumour as well as the surroundings
- Enhanced knowledge acquired regarding the biologic mechanisms and response rates



Dr David Krige,
Head of Biomarkers,
Immunocore Limited

10:40 Morning Networking Break

- 11:20 Harnessing natural bacterial products to develop pioneering and gentle immunotherapy treatments

- The potential to develop drugs from bugs
- Updates on the IMM-101 and IMM-201 clinical and pre-clinical development programmes
- Highlighting immune-modulatory mode of mechanism



Dr Laura Rosa Brunet,
Chief Scientific Officer,
Immodulun

IMMUNO-ONCOLOGY, CHRONIC & AUTOIMMUNE DISEASE APPROACHES

- 11:50 ABX196, a promising iNKT agonist to enhance therapeutic efficacy in oncology



Dr Hartmut J. Ehrlich,
Chief Executive Officer,
ABIVAX

12:20	Networking Lunch
13:20	Engineering 2nd Generation SPEAR™ T-cells to overcome TGF-β-mediated immunosuppression • NY-ESO SPEAR T-cells show promise in clinical trials for solid and liquid tumours • Depth and durability of responses may be affected by inhibitory cytokines such as Transforming Growth Factor-β (TGF-β) in the tumour microenvironment • Preclinical assessment of a dominant negative TGF-β receptor (dnTGFβRII) to make T-cells resistant to the inhibitory effects of TGF-β  Dr Jo Brewer, VP Platform Sciences, Adaptimmune
13:50	Targeting cancer neoantigens: a promising source of immunogens for cancer immunotherapy • Employing novel antibodies against immunogenic neoantigens • Antibody development using a novel platform exploiting immunogenic human tumour antigens • How to identify tumour specific monoclonal antibodies with anti-tumour activity and target antigens • Sharing pre-clinical and PhI clinical data in patients  Philip Arlen, President and Chief Executive Officer, Precision Biologics Inc
14:20	Enabling boosted anti-tumour immunity by use of an immuno-oncology-dedicated adenosine receptor antagonist • Sharing data updates • Characterization of a novel Adenosine A2A Receptor antagonist optimized to function in high adenosine concentrations within tumours • Defining the receptors essential for mediation of the effect of adenosine on immune cells within the tumour microenvironment • Translational strategy to improve the antitumor efficacy in patients  Dr Christophe Quéva, Chief Scientific Officer, iTeos Therapeutics SA
14:50	Immunoprofiling of tumour-draining lymph nodes: new targets for early intervention • Immunoprofiling of lymph nodes draining various tumour types has uncovered different immune suppressive mechanisms at play • Different combinations of locally applied TLR-ligands and/or immune checkpoint inhibitors should be considered for therapeutic conditioning of lymph nodes draining different tumour types. • Immune suppression of migratory and resident DC subsets in melanoma sentinel lymph nodes is differentially related to locoregional and distant metastasis. • Local immune modulation of melanoma-draining lymph nodes by CpG or anti-CTLA4 leads to systemic T-cell immunity and protection against metastatic spread.  Dr Tanja De Gruijl, Professor of Translational Tumor Immunology, V.U. Medisch Centrum
15:20	Chair's closing remarks and close of Congress

DAY 2 AGENDA

08:30

Chair's opening remarks



Nathalie Garcon,
CEO/CSO,
BIOASTER

CONTROL, PREVENTION & BREAKTHROUGH TRENDS CHANGING VETERINARY VACCINE LANDSCAPES

08:40

Maternal immunity: Opportunities and challenges within the veterinary landscape

- Discussing its role in vaccination and animal health
- Where do we stand right now? How can this strategy be effectively implemented?
- What hurdles need to be overcome?



Dr Mahesh Kumar,
Vice President,
Global Biologics Research, Zoetis

09:10

Prevention of food borne diseases through vaccination: challenges and opportunities in the global poultry industry

- Economic impact of Foodborne diseases to the Global Poultry Industry
- Emerging/re-emerging foodborne disease pathogens impacting the Global Poultry Industry
- Prevention of Food borne zoonosis through vaccination of Poultry: Challenges and opportunities



Nandakumar D Reddy,
Director,
Global Vaccine Research, Elanco

09:40

Disease prevention in relation to animal welfare

- The importance of risk control, identifying current and predicted risks and addressing how these can be minimised effectively
- Discussing the industry's role when concerning risk control and assessing how the industry can address the current risk control issue



Rik Koopman,
Global Technical Director,
MSD Animal Health

BIOPROCESSING, MANUFACTURING AND INNOVATIVE NEW TECHNOLOGY

10:10

Advancing veterinary vaccine innovation using novel biomarker technology

- Covering vaccine biomarker challenges in the pre-clinical and clinical spaces
- Development of biomarkers for adjuvants
- Steps forward for advancing vaccine biomarker research

10:40

Morning break

11:40

Interactive Roundtables

Choose 2 x 45 min long roundtables for these interactive discussions with like-minded peers tackling the same challenges – for more information go to **page 17**

13:10

Networking Lunch & Poster Session

14:40 Aerosol drug delivery technology for improved veterinary vaccination

- Pitfalls with current vaccination technologies
- Improving animal health, and vaccination efficiency, using high performance aerosol drug delivery technology

15:10 Manufacturing within the veterinary industry – The future of where it's going

- The significance of manufacturing quality control for veterinary vaccine development and vaccine efficacy
- New manufacturing technologies to that could potentially be commercially viable, and enable effective and rapid response during outbreaks
- Challenges the veterinary vaccine manufacturing is currently facing and steps to overcome these

**Randolph Seidler,**

Head of Global Business Development Animal Health,
Boehringer Ingelheim

15:45 Networking Lunch

16:15 The role of omics in veterinary vaccinology: Opportunities and challenges

- How can we exploit omics technology to advance veterinary innovation?
- Transcriptomics provide markers for potent adjuvants and vaccine efficacy
- Transcriptomics help to identify immunological processes crucial for vaccine-induced immunity

**Dr Artur Summerfield,**

Professor for Veterinary Immunology, Group Head,
Institute of Virology and Immunology

EMERGING AND RE-EMERGING DISEASES

16:45 African Swine Fever - Dealing with what is yet to come

- Addressing epidemiology and the increasing risk of its spread across Europe
- Developing vaccines to address ASF – where do we stand?
- Challenges needing to be overcome

**Dr Marisa Arias,**

Technical Director, EU Reference Laboratory for African swine fever,
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CISA)

17:15 Chair's closing remarks followed by **MEET & GREET WITH KEY SPEAKERS** in the **EXHIBITION HALL**

DAY 3 AGENDA

09:00

Chair's opening remarks



Nathalie Garcon,
CEO/CSO,
BIOASTER

EMERGING AND RE-EMERGING DISEASES

09:10

Developing veterinary vaccines for emerging and re-emerging diseases: gaps and requirements

- Key considerations when launching a veterinary vaccine development programme
- Highlighting the constraints that are enforced by national and European regulatory authorities and provide obstacles to obtaining market authorisation
- Promising areas of development



Dr Catherine Charreyre,
Head of Research Projects,
Merial

09:40

A transboundary problem: Lumpy Skin Disease (LSD)

- Reviewing the current spread of the disease and the role of the vectors and the environmental factors in the epidemiology of the disease
- Addressing the vital issue of vaccination against lumpy skin disease. Is vaccination the most effective control method?
- How can Europe effectively deal with this re-emerging challenge?



Dr Kris De Clercq,
Head of Unit,
CODA-CERVA (Veterinary and Agrochemical Research Centre)

10:10

Eradication and effective control methods against peste des petits ruminants

- Development of vaccines against PPRV and improved diagnostic tools for field use
- Analysis of the roles of specific viral and host proteins in viral genome and mRNA synthesis
- Addressing the challenges currently being faced and strategies to overcome these



Dr Arnaud Bataille,
Researcher in Virology, CIRAD,
Deputy Head, OIE/FAO Reference Laboratory for PPR
Deputy Head, EU Reference Laboratory for PPR

10:40

Networking Break

11:20

Application of DIVA vaccines to address Bovine Tuberculosis in cattle

- Discussing progress made on optimizing the only potentially available vaccine, Bacille Calmette Guérin (BCG)
- What strategies are there to improve BCG efficacy?
- Highlighting recent advances in DIVA development based on the detection of host cellular immune responses by blood-testing or skin-testing approaches
- What are the next steps necessary in order to accelerate DIVA vaccine development?



Martin Vordermeier,
Team Leader,
Animal Health and Veterinary Laboratories Agency

11:50

Producing several high efficacy vaccines to combat the re-emerged Blue Tongue Virus disease

- Sharing progressive updates on the rapid response to quickly produce several effective vaccines
- Challenges faced, steps taken to overcome these and thoughts for future emerging disease outbreaks.

12:20 Networking Lunch

13:20 The quest to develop new and improved vaccines for a range of economically important livestock diseases

- Research and data updates in line with Moredun's veterinary vaccine research
- Sharing information on development portfolio for vaccines for a range of endemic diseases, particularly parasitic diseases
- Case study: Barbevax, a vaccine against *Haemonchus* gastrointestinal worms in sheep



Dr Richard Mole,
Commercialisation Manager,
Moredun Research Institute

REGULATION, FUNDING AND PERSPECTIVES ON THE CURRENT VETERINARY VACCINE LANDSCAPES

13:50 Fast track licensing: Rapid registration of novel vaccine platforms panel

- Industry and regulatory perspectives
- Addressing acceleration of the licensing and registration process for new vet tech
- Hear from a company who has successfully registered a novel vaccine platform through fast track licensing.
- Discussing current challenges, hurdles faced, challenges overcome and thoughts for future

Dr Rosario Bullido, Head of Veterinary Immunological Medicines Assessment Unit Veterinary Medicines Department, **AEMPS**
Senior representative, IFAH-Europe

Philippe Migraine, Director Regulatory Affairs, **Biologicals New Projects, Merial**

Additional panellists to be confirmed shortly

14:50 Increasing availability of veterinary medicinal products through harmonisation of national regulation regarding autogenous farm specific vaccines

- The need to harmonise requirements and the understanding of "in the same locality", regarding the concept of epidemiological links between farms
- Discussing the importance of defining good practices regarding the manufacture and control of autogenous vaccines
- Considering potential implementation strategies to incorporate harmonisation within legislative framework



Jean de Foucauld,
Senior Bio Regulatory Expert,
Ceva

15:20 Harmonisation of registration requirements for veterinary vaccines in East Africa and a regional, time-based Mutual Recognition Procedure

- Harmonising technical requirements
- Development of a Mutual Recognition Procedure (MRP)
- Implementing MRP in the East African Community




Gillian Cowan,
Regulatory Affairs Consultant,
Global Alliance for Livestock Veterinary Medicines (GALVmed)

15:50 Chair's closing remarks and close of Congress

INTERACTIVE ROUNDTABLES



The 450+ vaccine & immune profiling attendees in 2016 came from



HOW WILL OUR SPONSORS & EXHIBITORS BENEFIT?

Over the course of the meeting in Barcelona all the sponsors and exhibitors will benefit from **direct F2F access with over 450 delegates**, where in total there will be over **8 hours of networking sessions** taking place. Different levels of partner involvement and activities offer the following:



PRESENTATIONS

High level sponsors are able to give full speaker case study presentations directly to potential and existing clients reinforcing their credibility and demonstrating thought leadership on specific topic areas.



EXHIBITION

With 30 exhibitors in total in 2016, they all have a unique opportunity to put their business products and services in front of potential buyers looking to source the latest technologies in the industry. This enables our clients to generate a high level of sales leads and form strong new relationships. All the complimentary buffet lunches and refreshments take place in this room, ensuring potential clients are in touching distance at all times when not in the conference.



HOST A ROUNDTABLE

On one of the days sponsors will have the opportunity to host/moderate one of the Roundtables discussions on a topic of their choice for 45 minutes. The session is part of the conference agenda so all attendees will see the topics and choose the tables of most interest to the subject matter, ensuring the sponsor will be in direct F2F discussion with 15-20 of the most relevant attendees at the event. Topic choices are based on a first come first served policy and naturally we won't be duplicating topic areas, so if you want to guarantee your topic focus area please let us know asap to avoid disappointment



BRAND AND POSITIONING

Through the associated company logo visibility on our banners and event marketing information on-site, the sponsors and exhibitors in Barcelona will be able to build their brand and positioning within the vaccine industry. This in turn will help them be seen as a leading solutions and service provider to new and existing customers, as well aligning themselves with industry bellwethers.



DRINKS RECEPTION

The drinks networking receptions at the end of each day will offer everyone the chance to unwind and relax in a more informal setting, developing further the business relationships that are initiated during the day. On the 10th October drinks and canapes will take place at an off-site venue, where 11th October drinks will take place within the exhibition room and form part of the "meet and greet" opportunity with some of the key speakers at the event.



NETWORKING MANAGER

As a high level sponsor there is the opportunity to have your own private networking manager for the event, who will work closely with you to facilitate and arrange 1-2-1 business meetings at the event. They will send out the attendee list approx. 4 weeks prior for the sponsor to choose pre-qualified targeted clients, and we will then assist pre-event and on-site for your team to have those meetings in your own reserved private meeting space.



JUBLIA NETWORKING SYSTEM

Jublia is our dedicated online networking tool used at the event by all the attendees, ensuring everyone focuses their time in valuable conversations and meetings with the right people for their business. It will be used at the event to ensure delegates manage their time onsite efficiently, can find attendees who share the same interests, can search for individuals by industry, company or name, can send and receive emails to the people they'd like to get in contact with, and set up their onsite meetings. Delegates are able to target and arrange to meet everyone they want to before the event begins via the on-line portal.

2017 FLOOR PLAN

Who will you meet?

- Innovators
- Disruptors
- Decision-Makers
- Influencers
- End-users from large and mid-cap vaccine manufacturers
- SME Biotech
- Academic
- Research Institutes
- Government Bodies
- Regulatory Boards
- Industry Solution Providers

This is a prime opportunity for:

- CROs
- CMOs
- Platform Technology Providers
- Fill / Finish
- Finished Dosage
- Platform Technology Providers
- Drug Delivery Providers
- Drug Diagnostic Providers
- Medical Device Manufacturers
- OEM /Equipment Providers
- Logistics Companies

Sponsorship opportunities include:

- Programme presence - from plenary to track sessions
- Exhibition
- Drinks Reception Sponsor
- Sponsor of the Scientific Poster Session
- Networking Break Sponsor
- Lanyard Sponsor
- Wi-Fi Sponsor
- Show Guide Sponsor



2017 SPONSORS AND EXHIBITORS

Sponsors



Exhibitors



Media Partners



RESERVE YOUR PLACE TODAY

The earlier you book, the more you'll save.

terrapinn.com/ImmuneEU17

PACKAGES	Before 21 April	Before 26 May	Before 23 June	Before 11 August	Before 1 Sept	Before 22 Sept	Final Price
Standard Package 3 days	€2140 SAVE €1430	€2510 SAVE €1060	€2850 SAVE €720	€3050 SAVE €520	€3230 SAVE €340	€3390 SAVE €180	€ 3,570
Academic & Regulatory Package 3 days	€1070 SAVE €715	€1255 SAVE €530	€1425 SAVE €360	€1525 SAVE €260	€1615 SAVE €170	€1695 SAVE €90	€ 1,785
Standard Package 2 days	€1550 SAVE €1035	€1810 SAVE €775	€2055 SAVE €530	€2190 SAVE €395	€2320 SAVE €265	€2450 SAVE €135	€ 2,585
Academic & Regulatory Package 2 days	€775 SAVE €520	€905 SAVE €390	€1030 SAVE €265	€1095 SAVE €200	€1160 SAVE €135	€1225 SAVE €70	€ 1,295
Display a Scientific Poster	€ 50						

BOOK NOW

Register at **terrapinn.com/ImmuneEU17**

Or call **+44 (0) 207 092 1210**

BRING YOUR TEAM

With three days packed full of great content and networking opportunities, you can't possibly cover it all alone!

Bring your team and get an extra discount. Call **+44 (0) 207 092 1210**